Parnax Lab

Parnax Lab EBITDA Margin

The EBITDA Margin of Parnax Lab (506128.BO) as of Nov 14, 2026 is 14.46 %. In the previous year, EBITDA Margin was 12.49 % — a change of 15.79% (higher).

EBITDA Margin

14.46 %

YoY

15.79%

Last updated:

EBITDA Margin of Parnax Lab is 2025 14.46 % . EBITDA Margin of Parnax Lab was 2024 12.49 % . It decreases by 15.79% higher compared to the previous year.

The Parnax Lab EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
10.61 INR
Jan 1, 2019
9.40 INR
Jan 1, 2020
6.75 INR
Jan 1, 2021
11.04 INR
Jan 1, 2022
14.13 INR
Jan 1, 2023
13.76 INR
Jan 1, 2024
12.49 INR
Jan 1, 2025
14.46 INR
The Parnax Lab EBITDA Margin history
YEAREBITDA MarginYoY
14.46 %+15.79%
12.49 %-9.29%
13.76 %-2.56%
14.13 %+27.90%
11.04 %+63.59%
6.75 %-28.15%
9.40 %-11.48%
10.61 %-21.13%
13.46 %-7.32%
14.52 %+18.95%
12.21 %-10.06%
13.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Parnax Lab Stock analysis

What does Parnax Lab do? Parnax Lab Ltd. generates revenue through manufacturing and exporting pharmaceutical formulations, including cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, geriatric special formulations, highly viscous products, and suspensions. The company trades pharmaceuticals and medicinal products, focusing on high-volume oral formulations for diverse consumer segments. Naxpar Pharma Private Limited serves as its subsidiary in these operations. The firm's primary customers are likely healthcare providers, pharmacies, and distributors within the pharmaceutical industry, though specific buyer details are not disclosed. Parnax Lab Ltd. operates through the pharmaceutical formulations segment, emphasizing export-driven manufacturing and trading activities. Its product portfolio targets various health needs, from pediatric to geriatric care, with a strong focus on oral delivery systems. Parnax Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Parnax Lab stock

EBITDA Margin of Parnax Lab is 14.46 % in 2025.

EBITDA Margin of Parnax Lab changed from 12.49 % to 14.46 %, representing a 15.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Parnax Lab since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Parnax Lab with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Parnax Lab

All Key Metrics — Parnax Lab